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ABSTRACT 
Background: Esophageal varices develop as a consequence of portal 
hypertension in patients with chronic liver disease and are present in 
approximately 50% of patients with cirrhosis of the liver. Mortality rate 
of an episode of esophageal varical bleeding is approximately 20% at six 
weeks. Predicting the grade of varices by non-invasive methods at the 
time of registration is likely to predict the need for prophylactic β 
blockers or endoscopic variceal ligation in patients with cirrhosis and 
portal hypertension. Therefore, the present study has been undertaken to 
determine the appropriateness of the various clinical, biochemical and 
imaging parameters in predicting the existence and also the grade of 
esophageal varices in cirrhosis of the liver. 
Methods: This was a prospective observational study which included 70 
patients with liver cirrhosis who satisfied the inclusion and exclusion 
criteria.All  patients included in the study were subjected to detailed 
history, clinical examination and blood investigations like liver function 
tests, complete blood counts including thrombocytopaenia, renal function 
tests, prothrombin time, Hepatitis B surface antigen, anti-HCV antibody. 
Ultrasonography of the abdomen  and Ascitic fluid analysis including 
SAAG  were done. And the patients were subjected to endoscopy. 
Results: Of the seventy cases studied, presence of varices increases as 
patients progress to decompensated liver disease (Child Pugh grade B & 
C ). Decrease in platelet count below 100000/μL was found to be a 
predictor of esophageal varices in patients with cirrhosis. Increase in 
prothrombin time more than 25 seconds is associated with grade 2,3 
varices. Value of serum ascitic albumin gradient (SAAG) more than 
1.4g/dl is found to be a predictor for presence and large grade of 
esophageal varices .Portal vein diameter more than 1.3cm is associated 
with linear increase in grade of varices. Majority of patients with marked 
hepatic encephalopathy had grade 3 varices. In patients with serum 
albumin less than 3g/dl most of the patients had grade 3 varices. 
Conclusion: A combination of these non invasive parameters in cirrhotic 
patients like platelet count, portal vein diameter, SAAG, Prothrombin 
time along with serum albumin, encephalopathy grade, Child pugh score 
for screening esophageal varices can substantially reduce the cost of 
health care and discomfort for patients as well as reduce burden on 
endoscopy units. 
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INTRODUCTION 
Esophageal varices develop as a consequence of portal 
hypertension in patients with chronic liver disease and are present in 
approximately 50% of patients with cirrhosis of the liver. The grade of 
esophageal varices often correlates with the severity of liver disease. 
While approximately 85% of individuals with Child Pugh C cirrhosis 
have varices, they are present in only 45% those with Child-Pugh A 
cirrhosis.[5]The rate of development of new varices and increase in 
grades of varices is 8% per year; the former is largely predicted by a 
hepatic venous pressure gradient (HVPG) exceeding 10 mm Hg[6,7]and 
the latter by the presence of decompensated cirrhosis, alcohol etiology 
and red wale signs[11]. 
Large size varices, the presence of red flag signs, severe liver 
disease and portal pressure greater than 12 mm Hg[8,9] predict greater 
risk of bleeding. Mortality rate of an episode of esophageal varical 
bleeding is approximately 20% at six weeks.[10,11]. 
Predicting the grade of varices by non-invasive methods at the time 
of registration is likely to predict the need for prophylactic β blockers or 
endoscopic variceal ligation in patients with cirrhosis and portal 
hypertension. Therefore, the present study has been undertaken to 
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determine the appropriateness of the various clinical, biochemical and 
imaging parameters in predicting the existence and also the grade of 
esophageal varices in cirrhosis of the liver. 
Its prevalence varies from 20-30% in patients with cirrhosis[8]. 
After varices have  developed, one-third of all patients die of bleeding 
gastro-esophageal varices[13]. The risk of initial bleeding from varices is 
25% to 35% within 2 years, with most first-bleeding episodes occurring 
within one year after detection of varices[10]. The reported mortality from  
the first episode of variceal bleeding in western studies ranges from 17% 
to 57%[15] as compared to 5-10% mortality reported in our population 
[16]. 
The Baveno III Consensus Conference on portal hypertension 
recommended that when liver cirrhosis is diagnosed ,all cirrhotic patients 
should be screened for the presence of esophageal varices.[14] Repeat 
endoscopy is recommended at 1–2 years interval in patients with small 
varices to evaluate the development or progression of varices and 2–3 
years interval in patients without varices [19].However, this approach has 
two major limitations.  
Endoscopy is an invasive procedure and secondly the cost 
effectiveness of endoscopy is also questionable[19] as only 9-36% patients 
with cirrhosis are found to have varices on screening endoscopy. It may 
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be more cost-effective when only high risk patients are routinely screened 
for the presence of varices so as to reduce the procedure cost and 
increasing burden of endoscopy units. There are factors that predict risk 
for first variceal hemorrhage[20]. Certain clinical, biochemical and 
ultrasonographic parameters either singly or in combination have good 
predictive power for non-invasively assessing the risk of bleeding from 
varices. However, the factors that predict the presence of varices are not 
as well defined. Identification of non-invasive predictors of esophageal 
varices will help us to carry out upper gestrointestinal endoscopy in 
selected group of patients thus avoiding unnecessary intervention and 
expenses, at the same time not missing high risk patients with increased 
chances of bleeding. 
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AIMS  &  OBJECTIVES 
1. To identify non invasive parameters for prediction of esophageal 
varices in newly diagnosed patients with cirrhosis, without 
previous     upper gastro intestinal bleed. 
2.  To assess the Predictive value of Portal vein diameter, Platelet 
count,  SAAG (Serum ascitic albumin gradient),in predicting 
esophageal varices in cirrhotic patients. 
3.  To assess the usefulness of prothrombin time in predicting  
esophageal varices in patients with cirrhosis. 
4.  To develop parameters for identifying candidates for upper gastro 
intestinal endoscopic screening.  
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                   REVIEW OF LITERATURE 
CIRRHOSIS 
Definition 
Cirrhosis is the end-stage manifestation of every chronic 
progressive liver disease. It is a diffuse process characterized by loss of 
hepatic parenchyma, formation of fibrous septa and structurally abnormal 
regenerative nodules, resulting in the distortion of the normal architecture 
and of gross vascular anatomy and microcirculation (21,22). 
Epidemiology 
Liver cirrhosis is a leading cause of death worldwide. It is the end 
result of a long-lasting process, usually clinically silent and unnoticed by 
the patient and the physician for years. In the past, up to 30–40% of cases 
have been discovered at autopsy (23). Due to the widespread use of 
imaging techniques, such as ultrasound and computed tomography it may 
be assumed that currently most cirrhotic livers are discovered earlier. 
Etiology  
Causes of liver cirrhosis 
Infectious 
Virus hepatitis B, C, D,  Schistosomiasis 
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Autoimmune 
Autoimmune hepatitis,Primary biliary cirrhosis, Autoimmune 
cholangitis, Overlap syndromes. 
Metabolic-toxic 
Ethanol, Nonalcoholic fatty liver disease (insulin resistance; 
metabolic syndrome),Indian childhood cirrhosis. 
Drug-induced 
 CCl4, arsenic,  methotrexate, isoniazid, amiodarone, a-
methyldopa. 
Genetic–hereditary 
Hereditary hemochromatosis, Wilson’s disease,a1-antitrypsin-
deficiency, Porphyria cutanea tarda, Glycogen storage diseases, 
Galactosemia, Tyrosinemia, Urea cycle disturbances, 
Abetalipoproteinemia, Cystic fibrosis. 
Biliary 
Secondary biliary cirrhosis (gallstones, strictures),Primary 
sclerosing cholangitis, Ischemic cholangiopathy, Ductopenia, bile duct 
atresia, Alagille's syndrome. 
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Vascular 
Chronic right heart failure ,Constrictive pericarditis, Budd-Chiari 
syndrome, Sinusoidal obstruction syndrome (venoocclusive 
disease),Hereditary hemorrhagic telangiectasia (Osler-Rendu-Weber 
disease). 
Cryptogenic 
Pathogenesis 
The following pathophysiological mechanisms are important in the 
development of liver cirrhosis 
• Hepatocyte death with loss of hepatic parenchyma 
• Fibrosis  
• Changes in cell growth (hyperplasia, regeneration) and 
• Vascular and circulatory alterations. 
Cell Death 
Chronic loss of hepatocytes is regarded as the primary stimulus and 
perpetuating factor in the development of liver cirrhosis. In order for 
cirrhosis to develop, liver cell loss must be sustained and long-lasting. 
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Liver injury may be mediated by immune mechanisms (for example 
cytotoxic lymphocytes attacking virally infected hepatocytes), 
inflammatory reactions (mediated by neutrophils and macrophages) or 
toxic factors (for example via oxidative stress and calcium-mediated 
cytotoxicity). 
Fibrosis and Circulatory Disturbances 
Fibrosis plays a crucial role in nodular transformation of the liver. 
However, it represents just one facet of liver cirrhosis and must not be 
equated with cirrhosis [24].Isolated fibrosis, even if extensive, does not 
necessarily result in cirrhosis. Cirrhosis is more than just widespread liver 
fibrosis. Further pathogenetic factors, such as liver cell loss and 
circulatory disturbances, must supervene in order for cirrhosis to develop. 
The development of liver cirrhosis is accompanied by a marked increase 
in collagen content and by deposition of extracellular matrix, both 
produced mainly by stellate cells, which are activated and transformed 
into myofibroblasts. Progressive disease is characterized by increasing 
fibrosis with fibrous tissue surrounding islands of hepatic parenchyma, 
thus leading to the formation of pseudolobuli. Fibrous septa may form 
bridges between portal tracts (portal-portal septa) and between portal 
tracts and central veins (portal-central septa). These remodeling processes 
are accompanied by hemodynamic alterations. Vascular channels within 
 
 
9 
 
the fibrous septa lead to the establishment of intrahepatic vascular shunts 
between afferent (portal vein and hepatic artery) and efferent (hepatic 
vein) vessels of the liver, which are significant for the development of the 
sequelae of liver cirrhosis. 
Disturbances in Hepatocyte Growth and Proliferation 
The proliferation of hepatocytes in a cirrhotic liver is viewed as a 
reactive regenerative process after cell loss. Regeneration, however, is 
incomplete, since complete restoration of normal hepatic architecture 
does not occur and the parenchymal defects are replenished by surrogate 
tissue. Generally, with advancing cirrhosis and increasing Child-Pugh 
stage the proliferation of hepatocytes decreases. Nodular transformation 
in cirrhosis of biliary origin is not pronounced until the late stages of the 
disease. In alcoholic cirrhosis, hepatocyte proliferation is inhibited which 
possibly contributes to the micronodular aspect of alcoholic cirrhosis. 
Pathology 
A simple, reproducible and comprehensible, macroscopical 
description of cirrhosis is its classification according to the size of 
nodules, specifically 
• Micronodular 
• Macronodular, and 
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• Mixed forms. 
Macroscopical Findings 
Micronodular Cirrhosis 
A liver cirrhosis in which nearly all nodules measure less than 
3mm in size. Typical causes for micronodular cirrhotic transformation are 
chronic alcohol abuse, bile duct obstruction, chronic venous outflow tract 
obstruction, hereditary hemochromatosis, Indian childhood cirrhosis. 
Macronodular Cirrhosis 
Macronodular cirrhosis is characterized by nodules greater than 3 
mm in size. Liver cirrhosis due to chronic viral hepatitis and autoimmune 
hepatitis is macronodular. Typical end-stage macronodular cirrhosis is 
small and hard (“shrunken liver”). 
Mixed Forms 
If the number of micronodules roughly equals that of 
macronodules, a mixed form of cirrhosis is said to be present. During the 
course of the disease micronodular cirrhosis may give way to the 
macronodular form. Viral superinfections, autoimmune processes and 
circulatory disturbances account for this transformation. Transformation 
of macrondular to micronodular cirrhosis does not occur. 
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DIAGNOSIS 
Clinical Manifestations 
Physical findings in patients with liver cirrhosis 
Ascites           : Portal hypertension, Hypoalbuminemia 
Hepatomegaly: Facultative; small liver in posthepatitic cirrhosis 
Splenomegaly : Portal hypertension 
Skin Changes   
Glazing lips and tongue  : papillary atrophy 
Oral rhagades  :  Zinc deficiency 
Spider angiomas  :  Central arteriole with radiating vessels 
                                                    due to increased estrogen 
“Banknote” skin   : Skin atrophy due to zinc deficiency 
Palmar erythema  :  ↑ estrogen 
Dupuytren’s disease :  Palmar fibromatosis; occurs 
predominantly in alcoholics 
Jaundice   : Advanced hepatocellular failure 
Purpura   :  Vascular fragility, thrombocytopenia 
Scratch signs  :  Pruritus 
Xanthelasma  :  Chronic biliary/cholestatic diseases 
Caput medusa  :  portal hypertension 
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Nail Changes 
White nails: Predominantly thumb and index finger 
Clubbed fingers/hour glass nails  :  In hepatopulmonary syndrome 
Endocrine Changes 
 Feminization in men, Abdominal baldness, ↓ Terminal hair in men, 
Testicular atrophy. 
Gynecomastia : Increased ratio of estrogen to free androgen due to 
decreased testosterone production, and increased 
peripheral conversion of testosterone to estradiol. 
Amenorrhea 
Foetor hepaticus  : Intestinal methylmercaptans  
Muscle atrophy  : Cytokines; malnutrition 
Parotid gland swelling: Malnutrition; predominantly in alcoholics. 
Laboratory Findings 
Aminotransferases  : Viral cirrhosis: ALT > AST 
Alcoholic cirrhosis: AST > ALT 
Parameters of Cholestasis:Biliary cirrhosis: ↑ALP and gGT 
Bilirubin: Serum level rises in advanced stage of cirrhosis 
Choline esterase: Parameter of hepatocyte synthetic capacity. Serum 
level decreases in advanced stage of cirrhosis. 
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Prothrombin time: Parameter of hepatocyte synthetic capacity. 
Prolonged in advanced stage of cirrhosis 
Albumin:  Parameter of hepatocyte synthetic capacity. Serum 
level decreases in advanced stage of cirrhosis 
g-globulins  Serum levels are increased with a broad based g-band 
on serum electrophoresis in 80% of patients with 
cirrhosis. g-globulins make up for 20–35% of all 
proteins. 
1)Autoimmune hepatitis: g-globulins increased in all 
patients. g-globulins > 50% of total protein. 
2)Primary biliary cirrhosis: ↑IgM 
3)Alcoholic cirrhosis: ↑IgA 
4)Viral cirrhosis: ↑IgG 
Blood count :Mild normo- to macrocytic anemia. Leukopenia, 
thrombocytopenia (hypersplenism) 
Ammonia:  Serum levels increased in advanced stage of cirrhosis. 
Levels do not correlate with signs and symptoms of 
hepatic encephalopathy 
Branched-chainamino acids: Serum levels decreased in advanced stage 
of cirrhosis 
Aromatic aminoacids: Serum levels increased in advanced stage of 
cirrhosis. 
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Imaging Techniques 
Imaging techniques play a leading role in the diagnosis of early 
stages of cirrhosis and in detecting focal (neoplastic) alterations in 
cirrhotic livers. Sonography, CT-scanning and magnetic resonance 
imaging are the prime imaging modalities in the diagnosis of cirrhosis. 
Course and Prognosis 
The natural history of cirrhosis is characterized by a “compensated 
phase”,  defined by the absence of complications, such as ascites, variceal 
bleeding, encephalopathy and by preserved synthetic and excretory 
functions(albumin ≥ 3.5 g/dL, INR ≤ 1.5, total bilirubin ≤ 1.5 mg/dL), 
followed by a rapidly progressive phase marked by increasing portal 
pressure and declining liver function, resulting in the development of 
ascites, portal hypertensive gastrointestinal bleeding, encephalopathy and/ 
or jaundice. The development of any of these complications defines the 
transition from a compensated to a “decompensated phase”. Transition 
from a compensated to a decompensated stage occurs at a rate of 5–7% 
per year. During a 10 year follow up of compensated viral cirrhosis, HCC 
develops in 21–32% of cases, followed by ascites (19.5–23%), jaundice 
(17%), upper gastrointestinal bleeding (4.5–6%), and encephalopathy (1–
2%) [25, 25, 26]. Survival of patients with compensated cirrhosis is 
significantly longer than that of decompensated patients with median 
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survival times of 12 years and 2 years, respectively. The mortality risk 
increases as the stage and the number of complication episodes increases 
[27,28]. 
Child-Pugh Classification of Cirrhosis 
Factor Units 1 2 3 
Serum bilirubin mol/L 
mg/dL 
<34 
<2.0 
34-51 
2.0-3.0 
>51 
>3.0 
Serum albumin g/L 
g/dL 
>35 
>3.5 
30-35 
3.0-3.5 
<30 
<3.0 
Prothrombin time seconds 
prolonged 
INR 
0-4 
 
<1.7 
4-6 
 
1.7-2.3 
>6 
 
>2.3 
Ascites   None Easily 
controlled 
Poorly controlled 
Hepatic encephalopathy   None Minimal Advanced 
 
 
Scoring occurs by adding the points for the various parameters. 
5–6 points: Child A (well compensated disease) 
7–9 points: Child B (significant loss of hepatic function) 
10–15 points: Child C (decompensated disease) 
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PORTAL HYPERTENSION 
Portal hypertension is defined as the elevation of the hepatic 
venous pressure gradient (HVPG) to >5 mmHg. Portal hypertension is 
caused by a combination of two simultaneously occurring hemodynamic 
processes: (1) increased intrahepatic resistance to the passage of blood 
flow through the liver due to cirrhosis and regenerative nodules, and (2) 
increased splanchnic blood flow secondary to vasodilation within the 
splanchnic vascular bed. Portal hypertension is directly responsible for 
the two major complications of cirrhosis: variceal hemorrhage and 
ascites. Varices are dilated, often tortuous veins. They occur most often in 
the distal esophagus and in the gastric fundus in patients with portal 
hypertension. Duodenal and rectal varices  rarely occur and are of minor 
clinical importance. 
Epidemiology 
Two thirds of all patients with liver cirrhosis with increasing portal 
hypertension develop esophageal varices and a portal hypertensive 
gastropathy . At the time of diagnosis of cirrhosis 60% of patients with 
decompensated and 30% of those with compensated cirrhosis already 
have varices. Approximately 10–15% of patients with esophageal varices 
concomitantly also have gastric fundal varices 
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The causes of portal hypertension are usually subcategorized as 
prehepatic, intrahepatic, and posthepatic. 
Classification of Portal Hypertension 
Prehepatic 
Portal vein thrombosis 
Splenic vein thrombosis 
Massive splenomegaly (Banti's syndrome) 
Hepatic 
Presinusoidal 
Schistosomiasis 
         Congenital hepatic fibrosis 
Sinusoidal 
        Cirrhosis—many causes 
        Alcoholic hepatitis 
  Postsinusoidal 
         Hepatic sinusoidal obstruction (venoocclusive syndrome) 
Posthepatic 
 Budd-Chiari syndrome 
 Inferior vena caval webs 
 Cardiac causes 
 Restrictive cardiomyopathy 
 Constrictive pericarditis 
 Severe congestive heart failure 
 
. 
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Anatomy, Etiology and Pathophysiology 
The veins of the esophageal wall consist of a subepithelial and a 
submucous plexus. Both plexus communicate through perforating veins. 
In the distal, precardiac esophagus the veins are mainly subepithelial. 
Esophageal varices are fed by the gastric coronary veins and the short 
gastric veins.  
The variceal pressure depends on the pressure gradient between the 
portal vein and the right atrium and varies with respiration. The mean 
variceal pressure is 20–25 cm H2O. The most important pathogenetic 
factor in the development and increase in size of gastroesophageal varices 
is portal hypertension. The hepatic venous pressure gradient (HVPG), 
determined by the difference between wedged and free hepatic venous 
pressure, is a good estimate of portal pressure. Varices start developing 
with HVPG values ≥10–12 mmHg [29].With increasing HVPG values 
both the transmural variceal pressure and the variceal wall tension rise, 
and the risk of bleeding increases [30]. 
Rarely esophagogastric varices may also develop in the absence of 
portal hypertension. Thus, for example, obstruction of the superior vena 
cava at the level of junction with the azygos vein, by increasing the 
outflow resistance of the azygos vein may lead to the development of 
isolated varices in the proximal esophagus (“downhill-varices”). 
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Mediastinal tumors, bronchial and esophageal cancer, goiter, fibrous 
adhesions or inadvertent ligation of vessels during thyroid resection may 
cause “downhill-varices”. Isolated fundal varices are usually due to an 
isolated block in the splenic vein. 
Diagnosis 
The diagnosis of subepithelial varices is made endoscopically. The 
dilated vessels protrude to a variable degree into the lumen, and their size 
and the appearance of the vessel wall may be assessed endoscopically. 
Both have prognostic significance. These aspects of the varices forms the 
basis for classifying them into different grades . The size of the varix 
must be graded. 
Grade 1 (F1): the varices can be depressed by the endoscope. 
Grade 2 (F2): the varices cannot be depressed by the endoscope. 
Grade 3 (F3): the varices are confluent around the circumference of the 
oesophagus. 
Laboratory findings, such as thrombocytopenia (<90,000/mL), 
splenomegaly, platelet count/spleen diameter ratio ,diameter of portal 
vein  (≥13 mm), lowered serum albumin and FibroTest have been 
proposed as noninvasive predictors of the presence of esophageal varices 
[30,31]. These parameters, however, especially when esophageal varices 
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are still small, are unreliable and do not substitute for endoscopy. In 
subjects with  liver cirrhosis the risk of having varices increases with 
decreasing platelet counts,increasing bilirubin concentration in serum, 
and rising INR.The probability of having medium or large varices at 
platelet counts >150,000/mm3 has been reported to be negligible. 
Course and Prognosis 
In patients with cirrhosis, esophageal varices develop at a rate of 
approximately 5–12% per year. If on initial endoscopy small (<5 mm) 
varices are present, the rate of progression to large varices is 
approximately 10–15% per year [33, 34].Varices may rupture and bleed. 
Approximately one third to one half of all patients with esophageal 
varices bleed at least once during their lifetime. Up to 25% of patients 
with newly diagnosed and untreated esophageal varices will bleed within 
the first 2 years after diagnosis.  
The risk of hemorrhage primarily depends on variceal size. It is 7% 
within 2 years in patients with small varices (diameter < 5 mm) and rises 
to 30% in those with large varices (diameter > 5 mm). Acute variceal 
bleeding always is a life threatening event and the risk of dying from the 
first variceal hemorrhage is approximately 20% [35,36].Without 
treatment, recurrent bleeding is the rule which in up to 20% of cases may 
occur as a fulminant  hemorrhage from fundal varices. Rebleeding occurs 
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within the first 6 weeks in 30% of cases and within 1 year after the first 
bleed in 70% of patients. The earlier the recurrence, the higher the 
mortality risk.  
The MELD score (≥18) is a good predictor of short-term (6 weeks 
to 3 months) mortality among cirrhotic patients at first episode of 
bleeding from esopahgeal varices [37]. Measurement of the HVPG 
obtained within 48 h of admission also may predict efficacy of treatment 
and short-term prognosis. However, it is not universally available and 
simple clinical variables, such as systolic blood pressure, Child-Pugh 
score and etiology of cirrhosis may be used instead as accurate predictors 
of short-term prognosis. Due to early and combined use of 
pharmacological and endoscopic therapies, and short-term antibiotic 
prophylaxis, in-hospital mortality of patients with cirrhosis and variceal 
bleeding decreased continuously over the past two decades [38]. 
Predictors of Variceal Bleeding 
Since variceal bleeding is associated with a high mortality risk, it is 
important to define predictors and to assess the risk of bleeding in order 
to establish effective prophylactic measures. The risk of variceal 
hemorrhage depends on the severity of liver disease (MELD score; Child-
Pugh score) and rises with decreasing liver function. The size of varices, 
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variceal pressure and the appearance of the surface of the vessel wall are 
important predictors of variceal bleeding. 
 Large vessels with high wall tension are more likely to bleed than 
small ones [38,39,40]. The wall tension correlates directly with 
transmural pressure and the diameter of a vessel and indirectly with wall 
thickness. It increases with rising portal pressure, increasing vessel size 
and decreasing wall thickness. Thus, not surprisingly, a large vessel with 
a thin wall will exhibit a higher wall tension than a small vessel with a 
thick wall and will therefore be more likely to rupture.  
The surface appearance of the vessel wall may yield important 
information regarding impending hemorrhage. Diffuse redness of the 
vessel, red color signs, such as “cherry red spots” and “red wale marks” 
(correspond to microtelangiectasia of the varix) and hemocystic spots 
looking like blood blisters (>4 mm; saccular aneurysm projections), are 
all thought to indicate a high risk for bleeding . A “white nipple sign” on 
a varix represents a platelet-fibrin plug and indicates previous bleeding 
but is not predictive of rebleeding [41].Every third patient with variceal 
hemorrhage, however, does not present these endoscopic signs.  
Thus, hemodynamic parameters are preferable in predicting the 
risk of variceal bleeding. The level of HVPG is a reliable and 
independent indicator for esophageal variceal bleeding. The normal value 
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of HVPG is 5 mmHg. Portal hypertension starts at a HVPG >5 mmHg, 
but values of >10–12 mmHg are clinically significant. With a HVPG 
<10–12 mmHg, varices do not develop, and preexisting varices do not 
bleed. Once HVPG increases to >12–16 mmHg, the risk of bleeding is 
high, but the degree of portal pressure elevation over 12 mmHg does not 
correlate directly with bleeding. 
Independent risk factors for esophageal variceal hemorrhage: 
1)Variceal characteristics 
• Size 
• Wall tension 
• Intravariceal pressure 
• Red colour signs 
2)Liver function (Child-Pugh-score; MELD score) 
3)Continuing alcohol abuse 
Prognostic significance of endoscopic and functional criteria for   
variceal bleeding: 
Endoscopic criteria Bleeding risk(%) 
1)Red wale markings  
Absent 19 
Mild 33 
Moderate 39 
Severe 80 
2)Variceal size  
Small  < 3 mm 18 
Medium  3–5 mm 29 
Large  > 5 mm 49 
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Endoscopic criteria Bleeding risk(%) 
3)Cherry-red-spots  
Absent 23 
Mild 32 
Moderate 40 
Severe 55 
4)Liver function (Child-Pugh-Score)  
Child A 17 
Child B 31 
Child C 39 
Portal vein diameter  
 It had been reported that portal vein diameter was an independent 
predictor for the presence of varices (42). However, few data are 
available about the relationship between portal vein diameter and LEV. 
Studies  showed that portal vein diameter was the second most important 
predictor for LEV in patients with a spleen width of ≤44.5 mm. However, 
it did not play an important role in predicting LEV in patients with spleen 
width of > 44.5 mm. 
Prothrombin time 
Prothrombin time is considered a marker of hepatocellular 
dysfunction. As portal hypertension is a consequence, in part, of the 
generalized vasodilation and the hyperdynamic splanchnic and systemic 
circulatory state, the degree of hepatic function likely affects the 
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development of portal hypertension via humoral factors and, therefore, 
the development of varices. Moreover, the degree of liver fibrosis is 
related to liver function and fibrosis can directly affect portal 
hypertension. It has been reported that serum fibrosis markers can detect 
LEV with a high accuracy, though several studies showed prothrombin 
time was associated with LEV on univariate analysis (43).  
SAAG and its association 
The development of the serum ascites-to-albumin gradient (SAAG) 
has replaced the description of exudative or transudative fluid. When the 
gradient between the serum albumin level and the ascitic fluid albumin 
level is >1.1g/dL, the cause of the ascites is most likely due to portal 
hypertension; this is usually in the setting of cirrhosis. When the gradient 
is <1.1 g/dL, infectious or malignant causes of ascites should be 
considered. When levels of ascitic fluid proteins are very low, patients are 
at increased risk for developing SBP. 
SAAG appears to retain its predictive value despite diuretics, 
infusion of albumin, therapeutic paracentesis or infection in the ascitic 
fluid. The finding of high SAAG denotes high chances of presence of 
esophageal varices in patients due to cirrhosis. 
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Prophylaxis and Therapy 
The management of patients with esophageal varices aims at three goals: 
• Prevention of first variceal hemorrhage (primary bleeding prophylaxis) 
• Treatment of acute variceal hemorrhage, and 
• Prevention of recurrent variceal hemorrhage (secondary bleeding 
prophylaxis) 
The outcome of the patients critically depends on the success of 
these measures. There is an increased array of therapeutic options 
including pharmacological, endoscopic, mechanically compressing 
(balloon tamponade), radiologic-invasive (TIPSS) and surgical 
techniques which may be applied according to the clinical situation[44, 
45]. 
Currently β-adrenergic blocking agents, nitrates, vasoconstrictors 
(e.g. terlipressin) and growth hormone inhibitors, such as somatostatin 
and octreotide are important. Endoscopic techniques encompass 
sclerotherapy and band ligation, surgical procedures include the creation 
of various portal-systemic shunts or the staple-gun transection of the 
esophagus as a salvage procedure for active variceal bleeding after failure 
of acute endoscopic therapy.  
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“Preprimary” Prophylaxis 
“Preprimary” prophylaxis refers to the prevention of the 
development of esophagogastric varices in patients with liver cirrhosis. 
The best way to achieve this goal is to successfully treat the underlying 
disease that leads to cirrhotic transformation. Beta-blockers are 
ineffective in preventing the development of varices in patients with 
cirrhosis [46]. For cirrhotic patients without varices, screening endoscopy 
every 3 years, or sooner if liver function deteriorates, is recommended.  
Primary Bleeding Prophylaxis 
Because every episode of variceal hemorrhage is associated with a 
high mortality rate, patients with cirrhosis and varices should be treated 
before the first bleeding occurs. Primary prophylaxis refers to the 
prevention of the first variceal hemorrhage and relies on measures like 
• Lowering portal venous pressure, and 
• Obliterating varices 
The first goal can be achieved by pharmacotherapy, the latter by 
endoscopic techniques. 
Pharmacotherapy. Nonselective b-blockers reduce portal-venous 
pressure by reducing cardiac output and splanchnic blood flow. In 
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addition, splanchnic vasoconstriction is enhanced by an uninhibited 
activation of α-receptors. Nonselective β- adrenergic antagonists are the 
mainstay of pharmacologic prevention of a first esophageal variceal 
hemorrhage [47]. The individual dose of β-blockers must be determined 
for each patient individually by adjusting the dose weekly with the goal 
of reducing heart rate by 25% from the baseline value   falling below a 
rate of 55/min or a systolic blood pressure of 90 mmHg (adjust to the 
maximal tolerated dose).  
Treatment with β-blockers is lifelong. Only patients in whom  β-
blockers lead to a durable decrease of HVPG < 12 mmHg or > 20% from 
baseline benefit from treatment. Falls in HVPG > 20% are associated 
with lower mortality [48]. In addition, reduction of HVPG also correlates 
with a reduced risk of spontaneous bacterial peritonitis or bacteremia . 
The β-blocker of choice is propranolol, 80–160 mg p.o. daily in 3–4 
divided doses; alternatively nadolol 20–240 mg p.o. daily can be used. 
Nadolol is less lipophilic than propranolol and does not cross the blood–
brain barrier. It is better tolerated and leads to less drug withdrawal (4%) 
due to side effects compared with propranolol (up to 30%).The use of b-
blockers also seems warranted in patients, with fundal varices as fundal 
and esophageal varices usually occur together. 
 
 
29 
 
Depending on Child-Pugh class, the number of patients needed to 
treat in order to prevent one bleeding episode is 5–14. The primary 
prophylactic effect of β-blockers seems to be more pronounced in 
patients with large varices and a high Child-Pugh score, which means that 
in order to achieve the same effect, fewer patients need to be treated. 
Primary prophylaxis with propranolol is cost-effective, even if compared 
with no therapy [49].Thus, despite their effectiveness in some patients, 
HVPG does not fall < 12 mmHg or ≥20% from baseline in up to two 
thirds of patients treated with β-blockers despite adequate  β-blockade. 
 Possibly Doppler patterns of splanchnic hemodynamics can serve 
as a non-invasive clue for the a prior identification of good and poor 
responders to β-blockers. Cirrhotic patients who responded poorly to 
nadolol, in contrast to good responders, showed a pronounced arterial 
splanchnic vasodilatation at a baseline echo-color-Doppler study. 
Therefore, in up to two thirds of patients treated with β-blockers and in 
15–25% with contraindications to β-blocker therapy or those who cannot 
tolerate the required doses because of untoward side effects, the question 
as to an alternative pharmacologic primary prophylaxis arises. 
 Long-acting oral nitrates, isosorbide mono- or dinitrate, because of 
their vasolidating effect lower both the systemic, splanchnic and portal 
pressure. Combined with β-blockers, the drop in pressure is slightly more 
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pronounced than with sole β-blocker therapy. Monotherapy with nitrates 
may impair renal function and worsen a pre-existing ascites. There are 
even worries that nitrates may increase the mortality rate. Therefore, 
nitrates should not be used as monotherapy in the prophylaxis of 
esophageal variceal bleeding. Carvedilol and the long-acting somatostatin 
analogue octreotide also reduce HVPG but both substances are not used 
in the long-term prevention of esophageal hemorrhage.  
Endoscopic Techniques. Endsocopic multiband ligation (EVL) of 
esophageal varices is safe and effective. It reduces the rate of first 
bleeding to 30–40% and the hemorrhage related mortality to 30% within 
2 years. Patients with compensated Child-Pugh class A cirrhosis benefit 
most from ligation. Most authors agree that in patients with high-risk 
esophageal varices, EVL is more effective than propranolol for the 
primary prevention of variceal bleeding [50]. However, there are also 
data showing that in patients in whom propranolol lowers HVPG 
effectively (<12 mmHg or a decrease of >20%), its efficacy is 
comparable to ligation . 
 If quality of life is considered, then EVL is similarly cost-effective 
as β-blockade .EVL is usually performed once every 2 weeks until 
varices are eradicated. Recent data show that EVL yields good results 
even if performed at bi-monthly intervals. Postbanding ulcers occur 
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regularly and usually are asymptomatic. Proton pump inhibitors may 
reduce their size. Endoscopic obliteration of varices is followed by 
lifelong treatment with β blockers. Endoscopic injection sclerotherapy is 
inferior to EVL and should not be performed in primary prophylaxis of 
esophageal varices. 
Therapy of Acute Variceal Hemorrhage 
Patients with acute variceal bleeding are managed in an intensive 
care unit. The first goal always is to secure vital functions. In somnolent 
patients, especially before performing the initial diagnostic endoscopy, 
endotracheal intubation is strongly advised. Erythromycin infusion (250 
mg) prior to endoscopy may improve stomach cleansing and quality of 
endoscopic examination in these patients. Prior to all hemostatic 
measures, stabilization of cardiocirculatory function is mandatory aiming 
at a systolic blood pressure of approximately 100mmHg and a 
haemoglobin value not more than 10 g/dL. Higher blood pressure and Hb 
values lead to an increase in portal pressure with a higher risk of recurrent 
bleeding. 
Pharmacotherapy 
 In suspected acute variceal bleeding vasoactive drugs should be 
started as soon as the diagnosis is made, even before diagnostic 
endoscopy. Vasoactive drug therapy should be maintained for 2–5 days. 
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Vasopressin lowers portal pressure by inducing contraction 
especially of the smooth muscle of splanchnic arterioles. However, 
vasopressin also causes systemic vasoconstriction which may lead to 
serious side effects, such as malignant cardiac arrhythmias, myocardial 
infarction, intestinal ischemia, cerebrovascular ischemia and local tissue 
necrosis. 
Terlipressin, a synthetic analog of vasopressin, Compared to the 
short acting vasopressin, the action of terlipressin is prolonged to 3–4 h 
and, most importantly, it does not show the dreaded side effects of 
vasopressinh Possibly the most important action of terlipressin is its 
beneficial effect on renal function in patients with the hepatorenal 
syndrome. 
Somatostatin has an effect comparable to terlipressin. It reduces  
splanchnic blood flow, has only few side effects (hyperglycemia) and is 
well tolerated.Octreotide,a long acting analog of somatostatin, has 
similar efficacy.      
Patients with marked hepatic coagulopathy may benefit from fresh 
frozen plasma. 
Bacterial infections in cirrhotic patients are associated with failure 
to control bleeding and represent an independent risk factor for recurrent 
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hemorrhage [52]. Antibiotic prophylaxis is an integral part of therapy for 
patients presenting with variceal bleeding and should be instituted from 
admission.  
Fluoroquinolones (ofloxacin, ciprofoxacin, levofloxacin, 
norfloxacin) or beta-lactams (amoxicillin-clavulanate, cephalosporins) are 
effective and reduce the risk of bacterial infections by about 30% and 
mortality risk by about 9% .Intravenous ceftriaxone (1 g qd) seems to be 
more effective than oral norfloxacin (400 mg bid) in the prophylaxis of 
bacterial infections in patients with advanced cirrhosis and hemorrhage . 
Endoscopic Techniques. Endoscopic therapy has a success rate of 
90%. It is the treatment of choice in patients with acute variceal 
hemorrhage and should be performed immediately after initial diagnostic 
endoscopy. Sclerotherapy and urgent band ligation are the endoscopic 
techniques available to stop acute variceal hemorrhage. Variceal band 
ligation is superior to sclerotherapy. 
Balloon Tamponade. If endoscopic emergency treatment is not 
readily available, if the bleeding is too rapid to permit endoscopy, or if 
medical and endoscopic therapy fails to control bleeding (for example, 
because of insufficient visualization for band ligation), balloon 
tamponade may achieve a satisfactory compression of the 
esophagogastric bleeding site in 80–90% of cases. The application of 
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balloon tamponade serves to gain time until definite hemostasis can be 
achieved. Because pressure ulcers may develop rapidly, tubes must be 
deblocked not later than 12 h after placement and then every 4–6 h for a 
period of 10 min. Complete large volume paracentesis lowers 
intravariceal pressure and improves respiratory function by lowering the 
diaphragm. 
TIPSS and Surgical Shunts: 
 If acute variceal bleeding is refractory to all of the above 
measures, surgical or nonsurgical shunting of portal blood to the systemic 
circulation is indicated as a salvage procedure. Both methods achieve 
acute hemostatic success rates of 90–100%. 
Prevention of Recurrent Variceal Hemorrhage 
Without adequate secondary prophylaxis approximately two thirds 
of patients rebleed within 6 weeks after the first variceal hemorrhage. 
Prevention of recurrent variceal hemorrhage is mandatory and is 
performed by combining band ligation with nonselective b-adrenergic 
blocking agents. The additional administration of β -blockers in patients 
in whom esophageal varices have been obliterated by banding further 
reduces mortality rate from 18% to 7% . The results of combining β-
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blockers (propranolol or nadolol) with long-acting nitrates (isosorbide 
mononitrate) in secondary prophylaxis are controversial. 
Shunt procedures should only be viewed as reserve techniques in 
secondary prophylaxis. Their excellent effect on portal hypertension and 
on lowering the rate of rebleeding is counterbalanced by the high 
encephalopathy rate. Surgical shunts should only be considered in 
recurrent bleeding in Child-Pugh class A patients. 
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MATERIALS AND METHODS 
Study Design: Prospective Observational Study. 
Study Population: 
Patients  admitted with complaints suggestive of liver cirrhosis in 
Medical Ward, GGH, Chennai, were taken into Study. 
Inclusion Criteria: 
Patients with cirrhosis of liver without any past history of upper 
(or) lower gastrointestinal bleed who were diagnosed based on history, 
physical findings, biochemical parameters, sonography and endoscopic 
methods. 
Exclusion criteria; 
1) Patients with history of upper or lower gastro intestinal bleed. 
2) Patients on previous/current treatment with drugs for portal 
hypertension. 
3) Patients who had undergone procedures for esophageal varices like 
banding , sclerotherapy injection (or) shunts. 
4) Patients with esophageal varices due to extra hepatic cause. 
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Ethical Clearance: Obtained. 
Informed Consent: Obtained from all patients.     
Methodology 
A total of 70 patients with liver cirrhosis were identified during the 
period of February 2011 to December 2011, according to the above 
criteria and were included in the study. All  patients included in the study 
were subjected to detailed history, clinical examination and blood 
investigations. 
History includes presence of jaundice, abdominal distension, pedal 
edema,oliguria, haemetemesis, malena, features suggestive of 
coagulopathy like gum bleed or hematuria included. Clinical examination 
of the study population was focussed on the presence of jaundice, 
,clubbing,dupuytrens contracture, loss of secondary sexual charecters, 
anemia, gynaecomastia, parotid enlargement, spider naevi, palmar 
erythema , testicular atrophy hepatic flap, splenomegaly and ascites, were  
noted. 
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Laboratory Investigations: 
All patients underwent biochemical tests, like liver function tests 
(serum bilirubin, ALT, AST, ALP, serum albumin), complete blood 
counts (haemoglobin, PCV, total and differential count, 
thrombocytopaenia), renal function tests(blood urea, serum creatinine), 
prothrombin time. Hepatitis B surface antigen and anti-HCV antibody 
were also investigated in all blood samples. ultrasonography of the 
abdomen was done to confirm the presence of cirrhosis and to find  portal 
vein diameter, ascites and presence of collaterals and Ascitic fluid 
analysis including SAAG in patients with ascites. 
 Chest X-ray and ECG were taken for all patients. Upper GI 
endoscopy was done in all patients to confirm the presence of varices and 
also to grade them.  
Statistical Analysis: 
Statistical analysis was done with 
1. SPSS software version 19 
2. Microsoft Excel 2010. 
Conflicts of interest: None 
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OBSERVATION  &  RESULTS 
RELATION BETWEEN SEX AND GRADE OF VARICES 
          Sex * Endoscopy Cross tabulation(Table 1) 
    P=0.763  
No significant gender difference in the distribution of grade of varices 
was found in our study. 
 
                  Sex
MaleFemale
Fr
eq
ue
nc
y
30
25
20
15
10
5
0
Endoscopy
       0
       1
       2
       3
     SEX  
                           Endoscopy-Grade of varices Total 
  0 1 2 3   
  
  
  
  
  
 
F  
  
No. of patients 0 7 4 3 14
% within Sex 0 50.0 28.6 21.4 100.0
% within Endoscopy 0 22.6 21.1 18.8 20.0
 
M  
  
No. of patients 4 24 15 13 56
% within Sex 7.1 42.9 26.8 23.2 100.0
% within Endoscopy 100.0 77.4 78.9 81.3 80.0
 
     Total  
  
No. of patients 4 31 19 16 70
% within Sex 5.7 44.3 27.1 22.9 100.0
% within Endoscopy 100.0 100.0 100.0 100.0 100.0
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RELATION BETWEEN AGE AND GRADE OF VARICES 
           Age Group in years * Endoscopy (Table 2) 
 Age Group in      
        years 
  
  
             Endoscopy-Grade of varices Total 
  0 1 2 3   
  
  
      Upto 40 
  
  
No. of patients 0 7 2 1 10
% within Age 
Group in years 0 70.0 20.0 10.0 100.0
% within 
Endoscopy 0 22.6 10.5 6.3 14.3
  
  
  
       41-50 
  
  
No. of patients 1 15 11 5 32
% within Age 
Group in years 3.1 46.9 34.4 15.6 100.0
% within 
Endoscopy 25.0 48.4 57.9 31.3 45.7
  
  
  
       51-60 
  
  
No. of patients 1 8 5 8 22
% within Age 
Group in years 4.5 36.4 22.7 36.4 100.0
% within 
Endoscopy 25.0 25.8 26.3 50.0 31.4
  
  
  
    Above 60 
  
  
No. of patients 2 1 1 2 6
% within Age 
Group in years 33.3 16.7 16.7 33.3 100.0
% within 
Endoscopy 50.0 3.2 5.3 12.5 8.6
 
 
       Total 
  
  
No. of patients 4 31 19 16 70
% within Age 
Group in years 5.7 44.3 27.1 22.9 100.0
% within 
Endoscopy 100 100 100 100 100
Pearson Chi-Square-16.600, P value-.055.  No significance in the 
distribution of age and grade of varices was found in our study. 
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RELATIONSHIP  BETWEEN  PLATELET COUNT AND  GRADE  
OF VARICES 
Platelet  count * Endoscopy Crosstabulation (Table 3) 
 
Platelet count/µL 
 
 
  
                  Endoscopy-Grade of varices Total 
 
P 
value   0 1 2 3   
  
  
<= 100000 
  
  
No. of patients 0 0 3 13 16
 
 
 
 
P 
<.001 
% within 
Platelet Count 0 0 18.8 81.3 100.0
% within 
Endoscopy 0 0 15.8 81.3 22.9
  
  
 100001-150000 
  
  
No. of patients 0 9 10 3 22
% within 
Platelet count 0 40.9 45.5 13.6 100.0
% within 
Endoscopy 0 29.0 52.6 18.8 31.4
  
  
150001-200000 
  
  
  
No. of patients 0 17 5 0 22
% within 
Platelet count 0 77.3 22.7 0 100.0
% within 
Endoscopy 0 54.8 26.3 0 31.4
  
  
  
   > 200000 
  
  
No. of patients 4 5 1 0 10
% within 
Platelet count 40.0 50.0 10.0 0 100.0
% within 
Endoscopy 100 16.1 5.3 0 14.3
 
 
        Total 
  
  
No. of patients 4 31 19 16 70
% within 
Platelet  count 5.7 44.3 27.1 22.9 100.0
% within 
Endoscopy 
100.
0 100.0 100.0 100.0 100.0
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Platelet count
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Pearson Chi-Square-72.996,P value-<.001,significant 
Out of the 70 patients,16 patients had platelet count less than 1 lakh 
of which 13 patients had grade 3 varices, and 3 patients with grade 2 
varices. And patients with platelet count above 2 lakhs none of them had 
grade 3 varices and one patient with grade 2 varices. The above 
observations suggested a strong association between a low platelet count 
and large varices, and a significant `P' value. 
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RELATIONSHIP  BETWEEN  PROTHROMBIN TIME  AND  
GRADE  OF VARICES 
Prothrombin time * Endoscopy Cross tabulation(Table 4) 
Prothrombin 
time(seconds) 
  
       Endoscopy- Grade of varices Total 
 
P value
  0 1 2 3   
  
  
    <= 15 
  
  
No. of patients 4 0 0 0 4 
 
 
 
 
 
 
 
 
 
 
P < 
.001 
% within 
Prothrombin 
time 
100 0 0 0 100.0 
% within 
Endoscopy 100 0 0 0 5.7 
  
  
  
     16-25 
  
  
No. of patients 0 26 1 0 27 
% within 
Prothrombin 
time 
0 96.3 3.7 0 100.0 
% within 
Endoscopy 0 83.9 5.3 0 38.6 
  
  
  
     26-35 
  
  
No. of patients 0 5 15 2 22 
% within 
Prothrombin 
time 
0 22.7 68.2 9.1 100.0 
% within 
Endoscopy 0 16.1 78.9
12.
5 31.4 
  
  
  
     > 35 
  
  
No. of patients 0 0 3 14 17 
% within 
Prothrombin 
time 
0 0 17.6 82.4 100.0 
% within 
Endoscopy 0 0 15.8
87.
5 24.3 
 
 
       Total 
  
  
No. of patients 4 31 19 16 70 
% within 
Prothrombin 
time 
5.7 44.3 27.1 22.9 100.0 
% within 
Endoscopy 100 100.0 100.
10
0.0 100.0 
Pearson Chi-Square-150.104 , P value < .001 
 
 
45 
 
34 out of 39 patients with Grade 2,3 varices had a prolonged 
prothrombin time more than 25 seconds, while in patients with a 
prothrombin time of less than 25 seconds majority had grade 1,0  varices. 
A significant 'p' value was observed. 
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RELATIONSHIP  BETWEEN  SERUM ALBUMIN AND  GRADE  
OF VARICES 
Serum albumin * Endoscopy Cross tabulation(Table 5) 
 Serum albumin 
        (g/dl) 
  
  
         Endoscopy- Grade of varices Total 
 
P value 
  0 1 2 3   
  
  
      <= 3 
  
  
No. of patients 0 0 2 15 17 
 
 
 
 
 
 
 
 
P < .001 
% within 
S.albumin 0 0 11.8 88.2 100.0 
% within 
Endoscopy 0 0 10.5 93.8 24.3 
  
  
  
      3-3.5 
  
  
No. of patients 0 1 15 1 17 
% within 
S.albumin 0 5.9 88.2 5.9 100.0 
% within 
Endoscopy 0 3.2 78.9 6.3 24.3 
  
  
  
     > 3.5 
  
  
No. of patients 4 30 2 0 36 
% within 
S.albumin 11.1 83.3 5.6 0 100.0 
% within 
Endoscopy 100.0 96.8 10.5 0 51.4 
 
       
      Total 
  
  
No. of patients 4 31 19 16 70 
% within 
S.albumin 5.7 44.3 27.1 22.9 100.0 
% within 
Endoscopy 100.0 100.0
100.
0
100.
0 100.0 
  
Pearson Chi-Square-102.562, P < .001 
In our sample with 70 patients, 17 patients had their serum albumin 
less than 3g/dl, who had grade 2,3 varices, in 36 patients the serum 
albumin is more than 3.5 with no varices or grade one varices. Value of 
serum albumin for patients showed inverse relationship with increasing 
grade of varices. `P' value was significant. 
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RELATIONSHIP  BETWEEN  ENCEPHALOPATHY AND  
GRADE  OF VARICES 
Encephalopathy * Endoscopy Crosstabulation (Table 6) 
 Encephalopathy
  
  
        Endoscopy- Grade of varices Total 
 
P value 
  0 1 2 3   
  
  
 
     Marked 
  
  
No. of patients 0 0 1 9 10 
 
P< .001 
% within 
Encephalopathy 0 0 10.0 90.0 100.0 
% within 
Encephalopathy 0 0 5.3 56.3 14.3 
  
  
       Mild 
  
  
No. of patients 0 2 15 7 24 
% within 
Encephalopathy 0 8.3 62.5 29.2 100.0 
% within 
Endoscopy 0 6.5 78.9 43.8 34.3 
  
  
  
           No 
  
  
No. of patients 4 29 3 0 36 
% within 
Encephalopathy 11.1 80.6 8.3 0 100.0 
% within 
Endoscopy 100 93.5 15.8 0 51.4 
 
 
        Total 
  
  
No. of patients 4 31 19 16 70 
% within 
Encephalopathy 5.7 44.3 27.1 22.9 100.0 
% within 
Endoscopy 100 100 100 100 100 
                      
Pearson Chi-Square-71.104, P < .001 
Hepatic encephalopathy had a linear relation with grade of varices. In our 
sample with 70 patients ,10 patients had marked hepatic encephalopathy, 
90% had grade 3 varices, in 24 patients there is mild hepatic 
encephalopathy  with 2/3 rd of patients having grade 2 varices. `P' value 
was significant. 
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RELATIONSHIP  BETWEEN  PORTAL VEIN DIAMETER AND        
GRADE  OF VARICES 
Portal Vein diameter * Endoscopy Cross tabulation (Table 7) 
  Portal Vein     
 Diameter(cms) 
  
  
             Endoscopy- Grade of varices Total 
 
P value 
  0 1 2 3   
  
  
1.00 
  
  
No. of patients 4 4 1 0 9 
 
 
 
 
P< .001 
% within Portal 
Vein diameter 44.4 44.4 11.1 0 100.0 
% within 
Endoscopy 100.0 12.9 5.3 0 12.9 
  
  
  
1.10 
  
  
No. of patients 0 23 4 0 27 
% within Portal 
Vein diameter 0 85.2 14.8 0 100.0 
% within 
Endoscopy 0 74.2 21.1 0 38.6 
  
  
  
1.20 
  
  
No. of patients 0 4 6 2 12 
% within Portal 
Vein diameter 0 33.3 50.0 16.7 100.0 
% within 
Endoscopy 0 12.9 31.6 12.5 17.1 
  
  
  
1.30 
  
  
No. of patients 0 0 6 3 9 
% within Portal 
Vein diameter 0 0 66.7 33.3 100.0 
% within 
Endoscopy 0 0 31.6 18.8 12.9 
  
  
  
1.40 
  
  
No. of patients 0 0 1 4 5 
% within Portal 
Vein diameter 0 0 20.0 80.0 100.0 
% within 
Endoscopy 0 0 5.3 25.0 7.1 
  
  
  
1.50 
  
  
No. of patients 0 0 0 6 6 
% within Portal 
Vein diameter 0 0 0
100.
0 100.0 
% within 
Endoscopy 0 0 0 37.5 8.6 
  
1.60 
No. of patients 0 0 0 1 1 
  % within Portal 0 0 0 100. 100.0 
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Vein diameter 0 
% within 
Endoscopy 0 0 0 6.3 1.4 
  
  
  
12.00 
  
  
No. of patients 0 0 1 0 1 
% within Portal 
Vein diameter 0 0 100 .0 100.0 
% within 
Endoscopy 0 0 5.3 .0 1.4 
 
 
       Total 
  
  
No. of patients 4 31 19 16 70 
% within Portal 
Vein diameter 5.7 44.3 27.1 22.9 100.0 
% within 
Endoscopy 100.0 100.0 100 100 100.0 
Pearson Chi-Square-95.6,   P value- < .001 
In patients with portal vein diameter <1.1cm none of them had Grade 2,3 
varices. Large varices were seen patients with portal vein diameter 
>1.4cm. The above observations suggested a strong association between a 
larger portal vein diameter with large varices, and a significant `P' value. 
 Portal Vein diameter
1.601.501.401.301.201.101.00
Fr
eq
ue
nc
y
30
20
10
0
Endoscopy
       0
       1
       2
       3
 
 
52 
 
RELATIONSHIP  BETWEEN SAAG(Serum Ascites Albumin 
Gradient) AND  GRADE  OF VARICES 
SAAG gradient * Endoscopy Crosstabulation (Table 8) 
 
 SAAG g/dl 
  
  
         Endoscopy – Grade of varices Total 
 
P value 
  0 1 2 3   
  
  
      1.1 
  
  
No. of patients 3 2 0 0 5 
 
 
 
P < .001 
% within Saag 60.0 40.0 0 0 100.0 
% within 
Endoscopy 75.0 6.5 0 0 7.1 
  
  
  
      1.2 
  
  
No. of patients 1 16 1 0 18 
% within Saag 5.6 88.9 5.6 0 100.0 
% within 
Endoscopy 25.0 51.6 5.3 0 25.7 
  
  
  
       1.3 
  
  
No. of patients 0 11 5 0 16 
% within Saag 0 68.8 31.3 0 100.0 
% within 
Endoscopy 0 35.5 26.3 0 22.9 
  
  
  
       1.4 
  
  
No. of patients 0 2 11 1 14 
% within Saag 0 14.3 78.6 7.1 100.0 
% within 
Endoscopy 0 6.5 57.9 6.3 20.0 
  
  
  
      1.5 
  
  
No. of patients 0 0 1 6 7 
% within Saag 0 0 14.3 85.7 100.0 
% within 
Endoscopy 0 0 5.3 37.5 10.0 
  
  
  
      1.6 
  
  
No. of patients 0 0 1 7 8 
% within Saag 0 0 12.5 87.5 100.0 
% within 
Endoscopy 0 0 5.3 43.8 11.4 
  No. of patients 0 0 0 2 2 
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      1.8 
  
  
  
  
% within Saag 0 0 0 100 100.0 
% within 
Endoscopy 0 0 0 12.5 2.9 
 
 
    Total 
  
  
No. of patients 4 31 19 16 70 
% within Saag 5.7 44.3 27.1 22.9 100.0 
% within 
Endoscopy 100.0 100.0 100.0 100 100.0 
 
SAAG
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Pearson Chi-Square-111.265, P < .001. 
 When the Value of SAAG was  between1.1 and 1.3  it was noted 
that Grade 3  varices were absent. When the SAAG values increased 
more than 1.3, there was considerable increase in grade  2,3varices. 
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RELATIONSHIP  BETWEEN  CTP SCORE AND    GRADE  OF 
VARICES 
CTP Score * Endoscopy Crosstabulation (Table 9) 
 
 CTP Score                       Endoscopy-Grade of varices Total 
    0 1 2 3  
 
  
      A 
  
  
No. of patients 4 13 0 0 17 
% within CTP 
Score 
23.5 76.5 0 0 100.0 
% within 
Endoscopy 100.0 41.9 0 0 24.3 
  
 
  
      B  
  
No. of patients 0 18 17 1 36 
% within CTP 
Score 
0 50.0 47.2 2.8 100.0 
% within 
Endoscopy 0 58.1 89.5 6.3 51.4 
  
 
  
      C   
  
No. of patients 0 0 2 15 17 
% within CTP 
Score 
0 0 11.8 88.2 100.0 
% within 
Endoscopy 0 0 10.5 93.8 24.3 
 
   Total 
No. of patients 4 31 19 16 70 
% within CTP 
Score 
5.7 44.3 27 22.9 100.0 
  % within 
Endoscopy 
100.0 100.0 100.0 100.0 100.0 
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Pearson Chi-Square-, P <77.71   . P<.001. 
Child Pugh score had a linear relation with grade of varices. In our 
sample with 70 patients, CTP score C found in 17 patients of which 15 
patients had grade 3 varices. CTP score A found in 17 patients of which 4 
patients did not had varices and 13 patients had grade 1 varices. P' value 
was significant. 
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DISCUSSION 
Our study sample consisted of 70 patients of whom 56 were male 
and 14 were females. No significant gender difference in the distribution 
of grade of varices was found in our study (Table 1). Distribution of 
grade of varices was studied in various age groups and no significant 
correlation was detected.(Table 2) 
We studied the frequency of distribution  of varices and found that 
Grade I predominated (42%),while  6 % of the study population did not 
have varices. 
Our study could find significant association between  
thrombocytopaenia and varices.(Table 3). An inverse relation between 
thrombocytopaenia and grade of varices is noted, out of 70 patients 44 
patients had platelet count less than 1.5lakhs,had grade 3,2 varices. 
Especially thae number of grade 3 varices increases when the platelet 
count was below 1 lakh. In  patients with platelet count above 2 lakhs 
grade 3 varices were not present and  only one patient had grade 2 
varices. 
PLATELET COUNT IN OTHER STUDIES PREDICTING 
OESOPHAGEAL VARICES 
Garcia- Tsao et al.[53](180 patients), Pilette et al.[54](116 patients) and 
K.Thomopoulos et al.[55](184 patients) reported a low platelet count to 
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be an independent risk factor for the presence of varices. Mohammad 
Khuram et  al.[56](200 patients) found esophageal varices in 146 with 
121 having thrombocytopenia (94.5%).Chalasani et al found that of 346 
patients, the presence of splenomegaly on physical examination (OR, 2.0; 
95% CI, 1.1-3.8) and a platelet count less than 88103/μL (OR, 1.6; 95% 
CI, 1.0-3.0) were independent risk factors for the presence of large 
varices.  
PROTHROMBIN TIME  IN VARIOUS STUDIES PREDICTING 
OESOPHAGEAL VARICES 
Our study could  find  significant association between prothrombin 
time  and varices. Higher the prothrombin time greater is the grade of 
varices (Table4)..Filippo Schepiset al reported that the presence of 
esophageal varices was independently predicted by prothrombin activity 
less than 70% (odds ratio [OR]: 5.83; 95% CI: 2.6-12.8). In a study by 
Pilette et al in a study of 116 patients with cirrhosis, a low platelet count, 
high prothrombin time, and the presence of spider angiomata were 
independent risk factors for the presence of varices. Paquet KJ.et al,[58] 
A prospective controlled trial, showed the importance of high 
prothrombin time  and association of varices. 
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SERUM ALBUMIN AND OESOPHAGEAL VARICES 
Our study could  find  significant association between serum 
albumin  and varices. Lower  the serum albumin levels the greater is the 
grade of varices  ( Table 5). In our sample with 70 patients, 17 patients 
had their serum albumin less than 3g/dl, had grade 2,3 varices.  In a 
logistic regression study by Garcia-Tsao et al of 180 patients, the 
presence of spider angiomata, a low albumin level, and a low platelet 
count were independent risk factors for the presence of varices. 
HEPATIC ENCEPHALOPATHY AND OESOPHAGEAL 
VARICES 
Our study could find significant association between hepatic 
encephalopathy and varices. Higher the encephalopathy grade greater is 
the grade of varices ( Table 6). 
PORTAL VEIN DIAMETER IN OTHER STUDIES PREDICTING 
OESOPHAGEAL VARICES 
Our study could  find  significant association between  Portal vein 
diameter and grade of varices. As the portal vein diameter increases the 
grade of varices also increases (Table 7). Grade 2,3 varices are seen with 
portal vein diameter more than 1.4cm. 
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Arulprakash Sarangapani et al, 2009, The study analyzed 106 
patients with liver diseases. On multivariate analysis, independent 
predictors for the presence of Large varices were, spleen size >13.8 mm, 
portal vein >13 mm, splenic vein >11.5 mm. 
Schepis et al [57] suggested that cirrhotic patients should be 
screened by upper gastrointestinal endoscopy when prothrombin activity 
was less than 70%, platelet count less than 100 × 109/L, and 
ultrasonographic portal vein diameter greater than 13 mm are observed, 
whereas those without any of these predictors should not undergo 
endoscopy. 
SAAG IN VARIOUS STUDIES PREDICTING OESOPHAGEAL 
VARICES 
Our study could find that, when the value of SAAG was  
between1.1 and 1.3  it was noted that Grade 3  varices were absent. When 
the SAAG values increased more than 1.3, there was considerable 
increase in grade  2,3varices. Kajani et al. [59]  reported that the portal 
pressure correlated with the SAAG only in patients with PHT caused by 
alcoholic liver disease. 
The SAAG is able to define the presence or absence of PHT with 
an accuracy of 96.7%. This test is accurate despite ascitic fluid infection, 
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diuresis, therapeutic paracentesis, albumin infusion, and etiology of liver 
diseases.  Gurubacharya et al the study included 32 patients with 
ascites, demonstrated by ultrasonography, who had measurement of the 
SAAG. All had upper gastrointestinal endoscopy with assessment of the 
presence and size of EV. High SAAG was considered to be present when 
SAAG was >=1.1 g/dl and Low SAAG when it measured < 1.1 g/dl. In a 
study performed by Hoefs et al. (1983)[60], it was shown that an excellent 
correlation exists between portal hypertension and SAAG .According to 
Goyal et al (1989) Serum ascites albumin gradient, showed a strong 
correlation to portal pressure, and was found to be the best diagnostic 
index (with an overall accuracy of 97 per cent). Demyrel et al (2003) 
study supports the observation that SAAG values increase in ascites due 
to portal hypertension. 
CTP IN VARIOUS STUDIES PREDICTING OESOPHAGEAL 
VARICES 
Our study could find that when the CTP score increases the 
variceal grade also increases. Of the 17 patients with CTP score C,15 
patients had grade 3 varices and similarly of the 17 patients with CTP 
score A none of the patients had grade 2,3 varices. (Table 9).The P value 
was significant.  
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In a study by Atif Zaman, et al. patients in CTP score B or C are 
nearly 3 times more likely to have large varices on upper endoscopy than 
are those in Child-Pugh score A. Cales et al, . In their study, multivariate 
analysis revealed that initial size of varices and interval worsening of the 
Child-Pugh score predicted the development of varices. 
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LIMITATIONS OF THE STUDY 
• The major limitation of the study was the smaller number of 
subjects. 
• Being a tertiary care center, the proportion of patients with more 
severe disease and multiple risk factors were getting admitted more 
than those with milder disease. 
• In our study female subjects were relatively less  because of overall 
lesser incidence of cirrhosis among female population. 
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SUMMARY AND CONCLUSION 
We studied seventy patients to find out non endoscopic predictors 
of esophageal varices in patients with cirrhosis who did not have previous 
history of upper gastrointestinal bleed. Presence of varices increases as 
patients progress to decompensated liver disease (Child Pugh grade B & 
C ). Decrease in platelet count below 100000/μL was found to be a 
predictor of esophageal varices in patients with cirrhosis. Increase in 
prothrombin time more than 25 seconds is associated with grade 2,3 
varices. Value of serum ascitic albumin gradient (SAAG) more than 
1.4g/dl is found to be a predictor for presence and large grade of 
esophageal varices .Portal vein diameter more than 1.3cm is associated 
with linear increase in grade of varices. Majority of patients with marked 
hepatic encephalopathy had grade 3 varices. In patients with serum 
albumin less than 3g/dl most of the patients had grade 3 varices. 
A combination of these non invasive parameters in cirrhotic 
patients like platelet count, portal vein diameter, SAAG, Prothrombin 
time  along with serum albumin, encephalopathy grade, Child pugh score 
for screening esophageal varices can substantially reduce the cost of 
health care and discomfort for patients as well as reduce burden on 
endoscopy units. 
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ANNEXURES 
                                 PROFORMA 
NON ENDOSCOPIC PREDICTORS OF OESOPHAGEAL 
VARICES IN PATIENTS WITH LIVER CIRRHOSIS 
1. Name 
2. Age/Sex: 
3. Address: 
4. IP No.                                
5. Occupation: 
6. Presenting illness 
Blood vomitting 
Black tarry stools 
Abdominal distension 
Pedal edema 
Jaundice 
Oliguria 
Altered sleep pattern/ consciousness level 
7.  Past history 
(DM/HT/Asthma/Seizures/Others/history of liver disease) 
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8. Personal history: 
(Alcohol, Smoking, IV drug abuse/Exposure to STD, Blood 
transfusion) 
9. Clinical examination: 
Pallor 
Icterus 
Clubbing 
Cyanosis 
Pedal Edema 
Significant lymphadenopathy 
KF ring 
              Signs of Liver cell failure 
              Vitals 
Pulse rate 
Blood Pressure 
Respiratory rate 
Temperature 
Signs of bleeding  
JVP 
           10. SYSTEM EXAMINATION 
                   Abdomen: Ascites, liver span, splenomegaly 
                   Respiratory system: 
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CVS Examination: 
CNS Examination: 
11. Investigations: 
Blood Biochemistry 
Complete Hemogram  
TC, DC, Hb, Platelet count 
Coagulation Profile 
          Blood sugar 
RFT 
Urea 
Creatinine 
Electrolytes 
LFT 
Total/Direct Bilirubin 
SGPT 
SGOT 
SAP 
Total protein, S.Albumin 
Viral markers (HBsAg, Anti HCV) 
Ascitic Fluid Analysis 
Protein/Sugar  
 Cell Count 
 
 
77 
 
Cytology 
Gramstain/AFB 
Culture 
SAAG ratio 
Chest X-ray 
ECG 
USG abdomen 
Portal vein size 
Spleen size 
Ascites 
Child's Grading: A/B/C 
UGI Endoscopy 
Varices grade  
          12. Treatment 
13. Outcome 
Discharge 
  Death 
 
